WHO monographs on selected medicinal plants - travolekar.ru

WHO monographs on selected medicinal plants - travolekar.ru WHO monographs on selected medicinal plants - travolekar.ru

20.01.2015 Views

ong>WHOong> ong>monographsong> on selected medicinal plants retarded the progression of cataracts in 97% (p < 0.05) of the subjects (n = 25) compared to 76% in the control group (n = 25) (17). However, several studies have also shown that administration of vitamin E alone reduces the incidence of cataracts (18). Extracts of the crude drug have also been tested in the treatment of glaucoma. In one small pilot study, eight patients with glaucoma were given a single dose of an extract of the crude drug containing 200.0 mg of anthocyanosides. Electroretinography showed improvements in all patients; however no further details are available (18, 33). Diabetic retinopathy In one report, oral administration of bilberry anthocyanins, at a dose of 600.0 mg/day for 6 months, to 32 patients with diabetes reduced the number of capillaries with lesions from 34% before treatment to 14% after treatment (2). In another investigation, 31 patients with various types of retinopathy were treated with an extract of the crude drug to determine the effect of anthocyanins on the retinal vessels. In patients with diabetic retinopathy, a reduction in permeability and tendency to haemorrhage was observed (34). In a randomized, double-blind, placebo-controlled study the effect of the crude drug was investigated in 40 patients with diabetic and/or hypertensive retinopathy. Patients were divided into two equal groups and either treated with a crude drug extract equivalent to 115 mg anthocyanosides daily, or a placebo, for 1 month. Retinopathy in the 20 patients receiving placebo remained unchanged and these patients were treated for a further 30 days. At the end of treatment (30 or 60 days), detectable retinal abnormalities (seen in 13/20 patients in the treatment group initially) were reduced in 10 patients and, in three, symptoms were unchanged. In the placebo group, retinal abnormalities (seen in 15/20 patients initially) were unchanged after 30 days, but when they were given active treatment for a further 30 days, 79% of patients improved (19). Myopia An extract of the crude drug containing 160 mg anthocyanins was investigated for its effect on myopia in 26 patients. Improvement of scotopic function was observed in all patients, but the effects were only statistically significant in subjects with slight myopia ( 6 diopters) (b2 wave, p < 0.01). In subjects with medium myopia, photopic function was significantly improved (critical central fusion frequency, p < 0.005; b1 wave, p

Fructus Myrtilli demonstrated. The final examination of 29 patients showed a stabilization of the fundus alterations, as well as a stable, or an improved visual acuity. In seven patients, a moderate deterioration of the partial or overall medical condition occurred (35). Night vision improvement The effect of the crude drug on the enhancement of night vision was first investigated by researchers in studies of Royal Air Force pilots during the Second World War. In these case-reports, the investigators suggested that there were improvements in night vision less than 24 hours after ingesting an unknown quantity of bilberry jam (36). Administration of the bilberry jam resulted in improved nighttime visual acuity, faster adjustment to darkness and faster restoration of visual acuity after exposure to glare (37, 38). Later studies supported these observations (36, 39, 40). Two studies showed that the administration of four tablets of an unspecified extract of the crude drug (100 mg per tablet) increased the light sensitivity threshold (36). However, these results have not been duplicated in controlled clinical trials. In one study, the ability of anthocyanosides in a single oral dose to improve night vision in normal individuals was evaluated during three night vision tests: full-field scotopic retinal threshold, dark adaptation rate and mesopic contrast sensitivity (41). The study, a double-blind, placebo-controlled, cross-over study, involved 16 young normal volunteers who were randomly assigned to one of four different regimens of single oral administrations of 12, 24 and 36 mg of anthocyanosides or a placebo, with a 2-week washout period between doses. Scotopic retinal threshold, dark adaptation rate and mesopic contrast sensitivity were measured immediately before, and 4, 8 and 24 hours after treatment. No significant effect of the treatment was found on any of the three night vision tests during the 24 hours following administration. The study concluded that single oral administration of 12–36 mg of anthocyanosides lacked any significant effect on night vision tests relevant to the military (41). In a controlled study, the ability of multiple oral doses of anthocyanosides to improve night vision in normal individuals was assessed. The effect was tested in the three night vision tests: scotopic retinal threshold, dark adaptation rate and mesopic contrast sensitivity. This double-blind, placebo-controlled, cross-over study involved 18 young normal volunteers who were randomly assigned to one of three different regimens of oral administrations of 12.0 and 24.0 mg/day anthocyanosides or a placebo, given twice daily for 4 days. A 2-week washout period was allowed between each 4-day treatment period. Scotopic retinal threshold, dark adaptation rate and mesopic contrast sensitivity tests were done 1 day before treatment and on days 1, 2, 3 and 4 during the treatment period. 219

<str<strong>on</strong>g>WHO</str<strong>on</strong>g> <str<strong>on</strong>g>m<strong>on</strong>ographs</str<strong>on</strong>g> <strong>on</strong> <strong>selected</strong> <strong>medicinal</strong> <strong>plants</strong><br />

retarded the progressi<strong>on</strong> of cataracts in 97% (p < 0.05) of the subjects<br />

(n = 25) compared to 76% in the c<strong>on</strong>trol group (n = 25) (17). However,<br />

several studies have also shown that administrati<strong>on</strong> of vitamin E al<strong>on</strong>e<br />

reduces the incidence of cataracts (18).<br />

Extracts of the c<strong>ru</strong>de d<strong>ru</strong>g have also been tested in the treatment of<br />

glaucoma. In <strong>on</strong>e small pilot study, eight patients with glaucoma were<br />

given a single dose of an extract of the c<strong>ru</strong>de d<strong>ru</strong>g c<strong>on</strong>taining 200.0 mg of<br />

anthocyanosides. Electroretinography showed improvements in all patients;<br />

however no further details are available (18, 33).<br />

Diabetic retinopathy<br />

In <strong>on</strong>e report, oral administrati<strong>on</strong> of bilberry anthocyanins, at a dose of<br />

600.0 mg/day for 6 m<strong>on</strong>ths, to 32 patients with diabetes reduced the number<br />

of capillaries with lesi<strong>on</strong>s from 34% before treatment to 14% after<br />

treatment (2). In another investigati<strong>on</strong>, 31 patients with various types of<br />

retinopathy were treated with an extract of the c<strong>ru</strong>de d<strong>ru</strong>g to determine<br />

the effect of anthocyanins <strong>on</strong> the retinal vessels. In patients with diabetic<br />

retinopathy, a reducti<strong>on</strong> in permeability and tendency to haemorrhage<br />

was observed (34). In a randomized, double-blind, placebo-c<strong>on</strong>trolled<br />

study the effect of the c<strong>ru</strong>de d<strong>ru</strong>g was investigated in 40 patients with diabetic<br />

and/or hypertensive retinopathy. Patients were divided into two<br />

equal groups and either treated with a c<strong>ru</strong>de d<strong>ru</strong>g extract equivalent to<br />

115 mg anthocyanosides daily, or a placebo, for 1 m<strong>on</strong>th. Retinopathy in<br />

the 20 patients receiving placebo remained unchanged and these patients<br />

were treated for a further 30 days. At the end of treatment (30 or 60 days),<br />

detectable retinal abnormalities (seen in 13/20 patients in the treatment<br />

group initially) were reduced in 10 patients and, in three, symptoms were<br />

unchanged. In the placebo group, retinal abnormalities (seen in 15/20 patients<br />

initially) were unchanged after 30 days, but when they were given<br />

active treatment for a further 30 days, 79% of patients improved (19).<br />

Myopia<br />

An extract of the c<strong>ru</strong>de d<strong>ru</strong>g c<strong>on</strong>taining 160 mg anthocyanins was investigated<br />

for its effect <strong>on</strong> myopia in 26 patients. Improvement of scotopic<br />

functi<strong>on</strong> was observed in all patients, but the effects were <strong>on</strong>ly statistically<br />

significant in subjects with slight myopia ( 6 diopters) (b2 wave,<br />

p < 0.01). In subjects with medium myopia, photopic functi<strong>on</strong> was significantly<br />

improved (critical central fusi<strong>on</strong> frequency, p < 0.005; b1 wave,<br />

p

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!